Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Sugarcoating matters

Financiado

Sugarcoating matters: Deciphering the effects of aberrant receptor N-glycosylati...

Sugarcoating matters: Deciphering the effects of aberrant receptor N-glycosylation on oncogenesis and drug resistance in acute myeloid leukemia During my post-doctoral studies, I have shown that sugarcoating of proteins, N-glycosylation specifically, is essential for the development and a potential therapeutic target in the blood cancer myeloproliferative neoplasms. Here,... ver más

31/01/2025

RADBOUDUMC

188K€

Presupuesto del proyecto: 188K€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-22

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

RADBOUDUMC

187.62K€ | Lider

Proyectos interesantes

MM_BH3_CutTag Parallel epigenomic and apoptotic profiling to identify targ... 216K€ Cerrado

PID2021-125282OB-I00 USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE... 472K€ Cerrado

M6ATCELL Exploiting fundamental insights of m6A methylation on CD8 T... 235K€ Cerrado

SAF2017-86327-R DESCIFRANDO NUEVAS FUNCIONES DE CAMBIOS EPIGENETICOS INDUCID... Cerrado

BFU2016-77408-R BASES ESTRUCTURALES DE LA INTERACCION ONCOGENICA DE LAS FOSF... 169K€ Cerrado

PID2019-111133RB-I00 VARIABILIDAD FENOTIPICA: ORIGENES Y CONSECUENCIA 169K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 29 meses Fecha Inicio: 2022-08-22
Fecha Fin: 2025-01-31

Presupuesto del proyecto 188K€

Descripción del proyecto During my post-doctoral studies, I have shown that sugarcoating of proteins, N-glycosylation specifically, is essential for the development and a potential therapeutic target in the blood cancer myeloproliferative neoplasms. Here, I show that differential expression of three enzymes that are key to protein sugar coating are strong novel prognostic factors in the blood cancer acute myeloid leukemia (AML). Specifically, these enzymes remove or add glucose molecules of the N-glycan sugar tree. Removal of the outer glucoses is essential for retaining N-glycoproteins within the endoplasmic reticulum (ER) and unprocessed N-glycans contain a high number of mannose sugars. I hypothesize that unprocessed N-glycoproteins such as growth receptors and drug removal pumps escape the ER and are expressed on the cell surface at a higher level due to abnormal expression of genes implicated in sugar coating (ALG10B, MOGS and PRKCSH). This in turn contributes to AML development and poor outcome. To proof my hypothesis, I will decipher the role of key enzymes in N-glycan glucose addition and removal to myeloid oncogenesis (aim 1A) and drug resistance (aim 1B) using colony forming unit assays and cell lines that express ALG10B or lack MOGS/PRKCSH (CRISPR-Cas9 knockout). Additionally, I will assess mannose abundance and targetability on primary AML versus healthy control bone marrow samples (aim 2A), and map N-glycan structures using recently developed high-throughput mass spectrometry and analyses techniques (aim 2B). I will correlate structural N-glycan profiles with expression of N-glycan processing enzymes assessed through RNA-sequencing to create a full picture of N-glycosylation aberrancies in AML. This study will decipher the molecular mechanisms underlying aberrant N-glycosylation in AML and provide anchor points for novel AML therapies. This is important, because the current 5-year overall survival rate of AML is only ~30% so therapy improvements are highly warranted.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores